Peer-influenced content. Sources you trust. No registration required. This is HCN.
These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.
Hematology January 19th 2021
Mayo Clinic
In this symposium preceding the ASH Annual Meeting on 12/4/20, the overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. The speakers will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
Hematology November 2nd 2020
In this “How I Treat” feature from Blood, the authors conclude with three representative cases to both illustrate the application of the outlined diagnostic schema and discuss common management considerations, specifically the selection of anticoagulation vs. antiplatelet therapy for secondary prevention.
Cardiology September 28th 2020
Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.
Allergy & Immunology April 27th 2020